Related Experiment Video
Updated: May 6, 2026
A Genetically Engineered Mouse Model of Sporadic Colorectal Cancer
Published on: July 6, 2017
Toward a Molecular Classification of Colorectal Cancer: The Role of MGMT
1Calgary Laboratory Services, Department of Pathology, University of Calgary , Calgary, AB , Canada.
Abstract:
O(6)-methylguanine DNA methyltransferase (MGMT) is a DNA repair enzyme with the ability to protect cells from DNA mutations by removing alkyl groups from the O(6) position of guanine. Colon mucosa is exposed to the direct effects of environmental carcinogens and therefore maintaining a proficient DNA repair system is very important to stay protected against DNA mutagenesis. Loss of MGMT expression is almost exclusively associated with methylation of CpG islands in the MGMT gene promoter region which is found in approximately 40% of colorectal cancers. The role of MGMT loss in colorectal tumorigenesis is complex but numerous studies have documented methylation of this gene even in the normal appearing mucosa as well as in aberrant crypt foci, suggesting that MGMT methylation can be regarded as an early event or "field defect" in colon cancer neoplasia. The focus of this perspective is the role of MGMT in different pathways of colorectal carcinogenesis as well as the implication of this molecule in treatment decisions in colorectal cancer patients.
Insights
O(6)-methylguanine DNA methyltransferase (MGMT) protects against DNA mutations. Loss of MGMT, often due to gene promoter methylation, is an early event in colorectal cancer development and impacts treatment decisions.
Area of Science:
- Molecular Biology
- Genetics
- Oncology
Background:
- O(6)-methylguanine DNA methyltransferase (MGMT) is a crucial DNA repair enzyme.
- Colon mucosa is vulnerable to environmental carcinogens, necessitating robust DNA repair.
- MGMT deficiency is linked to colorectal cancer development.
Purpose of the Study:
- To explore the role of MGMT in colorectal carcinogenesis pathways.
- To investigate the implications of MGMT status in colorectal cancer treatment decisions.
Main Methods:
- Review of existing literature on MGMT function and colorectal cancer.
- Analysis of MGMT gene promoter methylation in colorectal tissues.
- Correlation of MGMT status with cancer development and treatment response.
Main Results:
- MGMT loss is frequently associated with MGMT gene promoter methylation in colorectal cancers (approx. 40%).
- MGMT methylation occurs early in tumorigenesis, even in normal mucosa and aberrant crypt foci, suggesting a 'field defect'.
- MGMT status influences therapeutic strategies in colorectal cancer.
Conclusions:
- MGMT plays a significant role in protecting against colorectal carcinogenesis.
- MGMT promoter methylation is an early event in colon cancer development.
- MGMT status is a critical factor for guiding treatment decisions in colorectal cancer patients.
